The Company had $514M in cash, cash equivalents, and investments as of March 31, 2023."Our first quarter progress continues to establish Allogene as the leader in the development of allogeneic CAR T product candidates," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "Our success across multiple clinical programs, ability to attract top tier talent, and financial stewardship to weather the challenging external market environment paves the way toward to bringing a new generation of CAR T products to patients."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
- Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
- Allogene to present Phase 1 Data from ALLO-501/501A trials at ASCO
- Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
- Allogene Therapeutics appoints Timothy Moore as chief technical officer
